Research Establishes a New Method to Predict Individual Risk of Cognitive Decline
February 9, 2021
Lexington, KY, USA – The early prognosis of high-risk older adults for amnestic mild cognitive impairment (aMCI), using noninvasive and sensitive neuromarkers, is key for early prevention of Alzheimer’s disease. A recent study, published in the Journal of Alzheimer’s Disease, by researchers at the University of Kentucky establishes what they believe is a new way to predict the risk years before a clinical diagnosis. Their work shows that direct measures of brain signatures during mental activity are more sensitive and accurate predictors of memory decline than current standard behavioral testing.
“Many studies have measured electrophysiological rhythms during resting and sleep to predict Alzheimer’s risk. This study demonstrates that better predictions of a person’s cognitive risk can be made when the brain is challenged with a task. Additionally, we learned that out of thousands of possible brain oscillation measures, left-frontal brainwaves during so-called working memory tasks are good predictors for dementia risk,” explained lead investigator Yang Jiang, associate professor of behavioral sciences and an affiliated faculty member at the Sanders-Brown Center on Aging.
When looking for a specific car in a large parking lot, older persons increasingly make more mistakes and take more time than young people due to brain and cognitive aging. Jiang says it has already been reported that brain waves associated with that type of daily memory task differ in cognitively normal older people and those of patients with memory loss and dementia. For this new study, researchers followed healthy older adults for 10 years. They reported that a specific pattern of frontal brainwaves during an everyday memory task predicts a person’s risk of cognitive impairment roughly five years before clinical diagnosis. This pattern was not observed in older people who remained cognitively normal over the next 10 years.
Jiang says predicting and preventing cognitive decline is very important to allow preventive measures, such as life-style changes, and for researchers to help achieve a greater quality of life for the rapidly growing aging population. “Compared to current methods using neuroimaging as biomarkers, this method of measuring can be easily set up in clinics, is non-invasive, fast and affordable. Also, reliably predicting the risk of cognitive decline in an individual is new. Our older participants will soon be able to have better version of brainwave tests at the University of Kentucky”
The clinical and translation work of this study was a team science effort with multiple investigators from UK’s Sanders-Brown Center on Aging serving as coauthors including Erin Abner, Richard Kryscio, Greg Jicha, Fred Schmitt, Charles Smith, and collaborators from the Oak Ridge National Laboratory, University of Tennessee, and the Institute of Psychology, Beijing China.
This project was brought to SBCoA by scientists at the Oak Ridge National Laboratory co-author Nancy Munro to David Wekstein and Drs. William Markesbery and Charles Smith nearly 15 years ago with funding from the Department of Energy. The research team received funding from NIH in recent years to expand this work in large-scale and diverse populations. Jiang says their longitudinal study underscores the importance of having a successful Alzheimer’s research center at UK.
Linda Van Eldik, director of the Sanders-Brown Center on Aging, said, “This further emphasizes the long-standing national and international reputation of UK’s Sanders-Brown Center on Aging and the high quality of our investigators and the research they do.”
NOTES FOR EDITORS
Full open access study: “Memory-Related Frontal Brainwaves Predict Transition to Mild Cognitive Impairment in Healthy Older Individuals Five Years Before Diagnosis” by Yang Jiang, Juan Li, Frederick A. Schmitt, Gregory A. Jicha, Nancy B. Munro, Xiaopeng Zhao, Charles D. Smith, Richard J. Kryscio, and Erin L. Abner (DOI: 10.3233/JAD-200931), published in the Journal of Alzheimer’s Disease, Volume 79, Issue 2 (January 2021). The article is freely available at: content.iospress.com/articles/journal-of-alzheimers-disease/jad200931.
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers K01AG00986, R56AG060608-01, and P30AG028383. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This material is based upon work supported by Oak Ridge National Laboratory and UT-Battelle LLC for the U.S. Department of Energy under Award Number DE-AC05-00OR22725. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Energy or Oak Ridge National Laboratory.
For further information, please contact Hillary Smith, University of Kentucky (firstname.lastname@example.org, +1 8592301557).
About the Journal of Alzheimer’s Disease
Now in its 24th year of publication, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 3.909 according to Journal Citation Reports (Clarivate, 2020). The journal is published by IOS Press. j-alz.com